



ASX Announcement

Medlab presentation at Jefferies 2021 Healthcare Conference

- Speaking slot confirmed
- “replay” link available
- Focus, a patented delivery platform, enhancing a new medicine to provide a non-opioid solution

SYDNEY Australia: 27 May 2021: Medlab Limited (ASX: MDC), the Australian company commercialising an enhanced medicines delivery platform, today confirms the presentation by CEO Dr Sean Hall to the Jefferies 2021 Healthcare Conference on Wednesday 2 June will be available from 12:25am (AEST) equating to 10:25am US EST Tuesday 1 June.

Dr Hall plans to outline how Medlab is positioned to provide a potential solution to the global opioid pandemic by moving to a synthetic formulation favoured by regulators.

The presentation will highlight the significant regulatory, manufacturing and quality control advantages of moving to synthetic formulation which the Company believes will potentially deliver a faster path to multi-billion-dollar markets.

The presentation can be accessed via the following link which requires early registration:

<https://wsf.com/webcast/jeff174/mdc.ax/2053485>

A copy of Dr Hall’s presentation will be available on the ASX platform.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

For further information contact:

Dr Sean Hall

CEO Medlab Clinical

T: + 61 2 8203 9520

Follow us on Twitter [@medlabclinical](#)

LinkedIn [@medlab-pty-ltd/](#)

Medlab Clinical LTD (ASX: MDC) is pioneering the development and commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis may be equally effective in non-cancer neuropathic pain.

NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

Medlab – *better medicines, better patient care*